AIDS-related insulin resistance and lipodystrophy syndrome.

Tomoshige Kino, George P. Chrousos

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

The recent development of highly active antiretroviral therapy (HAART) has drastically improved the life expectancy of AIDS patients, by reducing infection-related mortality. However, the prolongation of the lives of HIV-1-infected patients and/or the long-term use of novel, potent antiviral agents have generated a score of new problems and complications. Among them is the AIDS-related insulin resistance and lipodystrophy syndrome, which is observed in 30-80% of AIDS patients who are well controlled by HAART. This syndrome is associated with severe metabolic disturbances, such as carbohydrate intolerance/diabetes mellitus and dyslipidemia, which cause atherosclerotic cardiovascular disease. The etiology of this syndrome appears to be multi-factorial; other than the anti-viral drugs, hypercytokinemia and the HIV-1 infection itself, including the virally encoded molecules Vpr and Tat, could contribute to the development of these pathologic changes or increase the vulnerability of patients to the adverse effect of the therapeutic compounds. In this article, we review our current understanding of the pathogenesis and therapeutic approach of this newly emerging AIDS-associated metabolic syndrome.

Original languageEnglish
Pages (from-to)111-117
Number of pages7
JournalCurrent drug targets. Immune, endocrine and metabolic disorders
Volume3
Issue number2
Publication statusPublished - Jun 2003
Externally publishedYes

Fingerprint

Lipodystrophy
Insulin Resistance
Acquired Immunodeficiency Syndrome
Highly Active Antiretroviral Therapy
HIV-1
Therapeutic Uses
Dyslipidemias
Life Expectancy
HIV Infections
Antiviral Agents
Diabetes Mellitus
Cardiovascular Diseases
Mortality
Infection
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Immunology and Allergy
  • Endocrinology, Diabetes and Metabolism

Cite this

AIDS-related insulin resistance and lipodystrophy syndrome. / Kino, Tomoshige; Chrousos, George P.

In: Current drug targets. Immune, endocrine and metabolic disorders, Vol. 3, No. 2, 06.2003, p. 111-117.

Research output: Contribution to journalReview article

@article{e12f4863a7064824a95f01adc3090daf,
title = "AIDS-related insulin resistance and lipodystrophy syndrome.",
abstract = "The recent development of highly active antiretroviral therapy (HAART) has drastically improved the life expectancy of AIDS patients, by reducing infection-related mortality. However, the prolongation of the lives of HIV-1-infected patients and/or the long-term use of novel, potent antiviral agents have generated a score of new problems and complications. Among them is the AIDS-related insulin resistance and lipodystrophy syndrome, which is observed in 30-80{\%} of AIDS patients who are well controlled by HAART. This syndrome is associated with severe metabolic disturbances, such as carbohydrate intolerance/diabetes mellitus and dyslipidemia, which cause atherosclerotic cardiovascular disease. The etiology of this syndrome appears to be multi-factorial; other than the anti-viral drugs, hypercytokinemia and the HIV-1 infection itself, including the virally encoded molecules Vpr and Tat, could contribute to the development of these pathologic changes or increase the vulnerability of patients to the adverse effect of the therapeutic compounds. In this article, we review our current understanding of the pathogenesis and therapeutic approach of this newly emerging AIDS-associated metabolic syndrome.",
author = "Tomoshige Kino and Chrousos, {George P.}",
year = "2003",
month = "6",
language = "English",
volume = "3",
pages = "111--117",
journal = "Endocrine, Metabolic and Immune Disorders - Drug Targets",
issn = "1871-5303",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - AIDS-related insulin resistance and lipodystrophy syndrome.

AU - Kino, Tomoshige

AU - Chrousos, George P.

PY - 2003/6

Y1 - 2003/6

N2 - The recent development of highly active antiretroviral therapy (HAART) has drastically improved the life expectancy of AIDS patients, by reducing infection-related mortality. However, the prolongation of the lives of HIV-1-infected patients and/or the long-term use of novel, potent antiviral agents have generated a score of new problems and complications. Among them is the AIDS-related insulin resistance and lipodystrophy syndrome, which is observed in 30-80% of AIDS patients who are well controlled by HAART. This syndrome is associated with severe metabolic disturbances, such as carbohydrate intolerance/diabetes mellitus and dyslipidemia, which cause atherosclerotic cardiovascular disease. The etiology of this syndrome appears to be multi-factorial; other than the anti-viral drugs, hypercytokinemia and the HIV-1 infection itself, including the virally encoded molecules Vpr and Tat, could contribute to the development of these pathologic changes or increase the vulnerability of patients to the adverse effect of the therapeutic compounds. In this article, we review our current understanding of the pathogenesis and therapeutic approach of this newly emerging AIDS-associated metabolic syndrome.

AB - The recent development of highly active antiretroviral therapy (HAART) has drastically improved the life expectancy of AIDS patients, by reducing infection-related mortality. However, the prolongation of the lives of HIV-1-infected patients and/or the long-term use of novel, potent antiviral agents have generated a score of new problems and complications. Among them is the AIDS-related insulin resistance and lipodystrophy syndrome, which is observed in 30-80% of AIDS patients who are well controlled by HAART. This syndrome is associated with severe metabolic disturbances, such as carbohydrate intolerance/diabetes mellitus and dyslipidemia, which cause atherosclerotic cardiovascular disease. The etiology of this syndrome appears to be multi-factorial; other than the anti-viral drugs, hypercytokinemia and the HIV-1 infection itself, including the virally encoded molecules Vpr and Tat, could contribute to the development of these pathologic changes or increase the vulnerability of patients to the adverse effect of the therapeutic compounds. In this article, we review our current understanding of the pathogenesis and therapeutic approach of this newly emerging AIDS-associated metabolic syndrome.

UR - http://www.scopus.com/inward/record.url?scp=0037507018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037507018&partnerID=8YFLogxK

M3 - Review article

VL - 3

SP - 111

EP - 117

JO - Endocrine, Metabolic and Immune Disorders - Drug Targets

JF - Endocrine, Metabolic and Immune Disorders - Drug Targets

SN - 1871-5303

IS - 2

ER -